Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stake Raised by Barclays PLC

Barclays PLC lifted its holdings in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 280.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 167,718 shares of the company’s stock after buying an additional 123,683 shares during the period. Barclays PLC owned approximately 0.13% of Atossa Therapeutics worth $255,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Atossa Therapeutics during the 2nd quarter worth $29,000. Intech Investment Management LLC bought a new stake in shares of Atossa Therapeutics during the third quarter valued at about $29,000. SG Americas Securities LLC lifted its holdings in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after purchasing an additional 30,037 shares during the period. The Manufacturers Life Insurance Company bought a new position in Atossa Therapeutics in the 3rd quarter valued at about $75,000. Finally, Rhumbline Advisers acquired a new position in Atossa Therapeutics during the 2nd quarter valued at about $161,000. 12.74% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research note on Thursday, December 12th. Ascendiant Capital Markets upped their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.

Atossa Therapeutics Trading Down 2.5 %

Shares of NASDAQ ATOS opened at $0.83 on Tuesday. The firm has a 50-day moving average of $1.10 and a two-hundred day moving average of $1.28. The company has a market capitalization of $103.87 million, a price-to-earnings ratio of -3.75 and a beta of 1.26. Atossa Therapeutics, Inc. has a twelve month low of $0.77 and a twelve month high of $2.31.

Atossa Therapeutics Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.